Video content above is prompted by the following:
- What underlying factors do you think contribute to the persistent under-treatment of VMS in menopausal women, despite the high prevalence of these symptoms?
- What factors contribute to patient resistance to conventional VMS treatment options, specifically hormone replacement therapies and nonhormonal therapies such as SSRIs [selective serotonin reuptake inhibitors] and gabapentin?
- How do untreated VMS impact the overall quality of life and long-term health outcomes for women, such as risk for cardiovascular disease and Alzheimer’s disease?
